GlassScriptPhysician profile
Hannah Bashaw Hoover
NPI 1497213227
$2,397.40
in general payments reported to CMS, 2019-2025
19 companies · $585 in 2025
The $585 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $413 · 2023: $398 · 2024: $369 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $464.26 | 2021-2024 | Austedo Xr |
| Dexcom, INC. | $332.75 | 2021-2023 | Dexcom G7 Gss (161) |
| Abbvie INC. | $247.92 | 2021-2025 | |
| Corcept Therapeutics | $227.78 | 2023-2024 | Korlym |
| Novo Nordisk INC | $179.96 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.26 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $149.05 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.10 | 2023-2025 | Jardiance |
| Rhythm Pharmaceuticals, INC. | $113.06 | 2021 | |
| Sumitomo Pharma America, INC. | $95.23 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $74.74 | 2025 | Airsupra, Breztri, Farxiga |
| Ibsa Pharma INC. | $70.45 | 2023-2025 | Licart, Tirosint, Flector |
| Exact Sciences Corporation | $45.30 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $28.92 | 2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $17.25 | 2025 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $15.69 | 2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.28 | 2025 | Caplyta |
| Boston Scientific Corporation | $14.21 | 2022 | |
| Antares Pharma, INC. | $14.19 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Hoover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.